Trending:
Industry News
-
17 January 2019
Report finds NICE unaware of financial interests of patient groups
A report by the London School of Tropical Medicine (LSTM) found that patient organisations consulted by the UK’s National institute of Health and Care Excellence (NICE) to advise on appraisals...
-
17 January 2019
European and UK pharma industry call for action as parliament rejects Brexit deal
The UK pharma industry has called for preparations to ensure that patients will have access to their medications in case of a no-deal Brexit by 30 March 2019.
-
16 January 2019
FDA announces new policies for cell and gene therapies
Despite most of the US Food and Drug Administration’s (FDA) responsibilities grinding to a halt as a result of the US Government shut down, FDA commissioner Scott Gottlieb and Centre...
-
16 January 2019
US Oversight Committee launches drug price probe into major companies
The US Committee on Oversight and Reform chairman Elijah Cummings has launched an investigation into the drug pricing practices of multiple pharmaceutical companies.
-
14 January 2019
UK and Japan partner on treatments for degenerative diseases
Medical researchers in the UK and Japan are set to work together on advancing research aimed at developing treatments for chronic degenerative and incurable diseases, including diabetes and heart disease.
-
11 January 2019
US lawmakers to introduce new bills to slash prescription drug prices
US Senator Bernie Sanders and Representative Elijah Cummings have announced plans to introduce three new bills to reduce the price of prescription drugs in the country.
-
7 January 2019
NHS Long Term Plan: focus on R&D and digital innovation
The UK Government has launched the NHS Long Term Plan laying out the health service's focuses for the next decade. Two of the most interesting aspects are better focused R&D...
-
2 January 2019
Pharma companies break 2018 price freeze
On 1 January approximately 30 pharmaceutical companies raised the prices of hundreds of drugs in the US by an average of 6.3%, following a year of price freezes.
-
13 December 2018
Janssen’s Tremfya shows superiority in plaque psoriasis to Novartis’ drug at 48 weeks
Johnson & Johnson subsidiary Janssen has announced results from its phase III Eclipse trial comparing its Tremfya (guselkumab) with Novartis’ Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis.
-
11 December 2018
New Zealand moves towards legalising medical cannabis
New Zealand’s parliament has passed an amendment to the Misuse of Drugs Act 1975 that will allow terminally ill patients to possess and use cannabis.